Research Archive — Page 55 of 134
-
August 4, 2022
Study tracks limited use of influenza antiviral therapy
A Vanderbilt study found that more than half of children diagnosed with influenza and deemed high risk for flu-related complications were given the recommended antiviral treatment. -
August 2, 2022
Targeted cancer drug during pregnancy
The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians. -
August 1, 2022
H. pylori and lung cancer
Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered. -
July 28, 2022
Video vital for telehealth visits
Vanderbilt study of 18,130 telehealth visits at the beginning of the COVID-19 pandemic defines risk factors associated with telehealth access and suggests how health systems can improve access. -
July 28, 2022
Specialty pharmacists help reduce MS relapse risk
Just one-third of patients with relapsing multiple sclerosis remain on disease-modifying therapy, and specialty pharmacists are in a unique position to help coordinate therapy discontinuation or change and reduce the risk of relapse. -
July 28, 2022
C. difficile may contribute to colorectal cancer: study
A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer. -
July 28, 2022
Study reveals need for matching targeted therapies with EGFR subtypes
A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.